Aptose Biosciences Inc. (APS.TO)
CAD 0.27
(0.0%)
CAD 0.27
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 52.35 Million USD | 22.9% |
| 2022 | 42.6 Million USD | -34.91% |
| 2021 | 65.44 Million USD | 17.36% |
| 2020 | 55.76 Million USD | 107.65% |
| 2019 | 26.85 Million USD | -7.73% |
| 2018 | 29.1 Million USD | 146.13% |
| 2017 | 11.82 Million USD | -14.84% |
| 2016 | 13.88 Million USD | 19.71% |
| 2015 | 11.6 Million USD | -1.94% |
| 2014 | 11.83 Million USD | 33.61% |
| 2013 | 8.85 Million USD | 63.29% |
| 2012 | 5.42 Million USD | 21.48% |
| 2011 | 4.46 Million USD | -12.46% |
| 2010 | 5.09 Million USD | -6.32% |
| 2009 | 5.44 Million USD | -19.28% |
| 2008 | 6.74 Million USD | -39.11% |
| 2007 | 11.07 Million USD | 43.63% |
| 2006 | 7.71 Million USD | -48.96% |
| 2005 | 15.1 Million USD | 187.06% |
| 2004 | -17.35 Million USD | -173.61% |
| 2003 | 23.57 Million USD | 281.34% |
| 2002 | -13 Million USD | -228.32% |
| 2001 | 10.13 Million USD | -21.78% |
| 2000 | 12.95 Million USD | 83.81% |
| 1999 | 7.04 Million USD | 99.81% |
| 1998 | 3.52 Million USD | 0.72% |
| 1997 | 3.5 Million USD | -1.52% |
| 1996 | 3.55 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 9.76 Million USD | -19.52% |
| 2024 Q2 | 7.34 Million USD | -24.74% |
| 2023 FY | 52.35 Million USD | 22.9% |
| 2023 Q1 | 14.09 Million USD | 35.5% |
| 2023 Q2 | 14.45 Million USD | 2.53% |
| 2023 Q3 | 11.68 Million USD | -19.17% |
| 2023 Q4 | 12.12 Million USD | 3.82% |
| 2022 FY | 42.6 Million USD | -34.91% |
| 2022 Q4 | 10.4 Million USD | 3.76% |
| 2022 Q1 | 11.5 Million USD | -52.77% |
| 2022 Q2 | 10.67 Million USD | -7.19% |
| 2022 Q3 | 10.02 Million USD | -6.06% |
| 2021 Q3 | 11.35 Million USD | -15.78% |
| 2021 Q4 | 24.34 Million USD | 114.35% |
| 2021 Q2 | 13.48 Million USD | -17.01% |
| 2021 Q1 | 16.25 Million USD | 10.12% |
| 2021 FY | 65.44 Million USD | 17.36% |
| 2020 Q1 | 11.83 Million USD | 50.1% |
| 2020 Q2 | 15.88 Million USD | 34.2% |
| 2020 Q4 | 14.75 Million USD | 11.02% |
| 2020 Q3 | 13.29 Million USD | -16.29% |
| 2020 FY | 55.76 Million USD | 107.65% |
| 2019 Q3 | 7.02 Million USD | 10.73% |
| 2019 Q2 | 6.34 Million USD | 13.32% |
| 2019 Q1 | 5.6 Million USD | -11.46% |
| 2019 FY | 26.85 Million USD | -7.73% |
| 2019 Q4 | 7.88 Million USD | 12.2% |
| 2018 Q3 | 5.61 Million USD | -45.68% |
| 2018 FY | 29.1 Million USD | 146.13% |
| 2018 Q1 | 6.84 Million USD | 136.85% |
| 2018 Q2 | 10.32 Million USD | 50.96% |
| 2018 Q4 | 6.32 Million USD | 12.73% |
| 2017 Q3 | 2.73 Million USD | 8.05% |
| 2017 FY | 11.82 Million USD | -14.84% |
| 2017 Q1 | 3.29 Million USD | 10.46% |
| 2017 Q2 | 2.53 Million USD | -23.14% |
| 2017 Q4 | 2.88 Million USD | 5.52% |
| 2016 FY | 13.88 Million USD | 19.71% |
| 2016 Q4 | 2.98 Million USD | -4.21% |
| 2016 Q3 | 3.11 Million USD | -28.48% |
| 2016 Q2 | 4.35 Million USD | 14.86% |
| 2016 Q1 | 3.79 Million USD | 11.88% |
| 2015 FY | 11.6 Million USD | -1.94% |
| 2015 Q1 | 2.88 Million USD | -9.13% |
| 2015 Q4 | 3.38 Million USD | 14.63% |
| 2015 Q3 | 2.95 Million USD | -3.71% |
| 2015 Q2 | 3.07 Million USD | 6.58% |
| 2014 FY | 11.83 Million USD | 33.61% |
| 2014 Q4 | 3.17 Million USD | 82128.54% |
| 2014 Q3 | 3856.23 USD | -99.9% |
| 2014 Q2 | 3.87 Million USD | 82.18% |
| 2014 Q1 | 2.12 Million USD | -17.2% |
| 2013 FY | 8.85 Million USD | 63.29% |
| 2013 Q4 | 2.57 Million USD | 154.2% |
| 2013 Q2 | 1.25 Million USD | -7.07% |
| 2013 Q3 | 1.01 Million USD | -19.28% |
| 2013 Q1 | 1.34 Million USD | -17.55% |
| 2012 FY | 5.42 Million USD | 21.48% |
| 2012 Q1 | 1.02 Million USD | -27.25% |
| 2012 Q2 | 839.02 Thousand USD | -18.38% |
| 2012 Q3 | 1.27 Million USD | 51.59% |
| 2012 Q4 | 1.63 Million USD | 28.54% |
| 2011 Q2 | 1.07 Million USD | -34.04% |
| 2011 Q1 | 1.62 Million USD | 36.5% |
| 2011 Q3 | 1.14 Million USD | 7.07% |
| 2011 Q4 | 1.41 Million USD | 23.28% |
| 2011 FY | 4.46 Million USD | -12.46% |
| 2010 Q3 | 1.07 Million USD | -38.54% |
| 2010 FY | 5.09 Million USD | -6.32% |
| 2010 Q1 | 1.28 Million USD | 1.68% |
| 2010 Q2 | 1.75 Million USD | 36.51% |
| 2010 Q4 | 1.18 Million USD | 10.48% |
| 2009 FY | 5.44 Million USD | -19.28% |
| 2009 Q4 | 1.26 Million USD | 15.21% |
| 2009 Q3 | 1.09 Million USD | -46.02% |
| 2009 Q2 | 2.02 Million USD | 26.77% |
| 2009 Q1 | 1.59 Million USD | 10.25% |
| 2008 Q1 | 3.48 Million USD | 30.54% |
| 2008 Q2 | 3.09 Million USD | -11.3% |
| 2008 FY | 6.74 Million USD | -39.11% |
| 2008 Q3 | 2.02 Million USD | -34.48% |
| 2008 Q4 | 1.45 Million USD | -28.39% |
| 2007 Q1 | 1.48 Million USD | -39.7% |
| 2007 Q4 | 2.67 Million USD | 62.98% |
| 2007 Q3 | 1.63 Million USD | -9.78% |
| 2007 Q2 | 1.81 Million USD | 22.52% |
| 2007 FY | 11.07 Million USD | 43.63% |
| 2006 Q1 | 3.3 Million USD | -19.88% |
| 2006 FY | 7.71 Million USD | -48.96% |
| 2006 Q4 | 2.45 Million USD | 15.26% |
| 2006 Q3 | 2.13 Million USD | -22.81% |
| 2006 Q2 | 2.76 Million USD | -16.29% |
| 2005 Q2 | -31.56 Million USD | -854.65% |
| 2005 Q1 | 4.18 Million USD | -17.0% |
| 2005 Q4 | 4.12 Million USD | -10.61% |
| 2005 Q3 | 4.6 Million USD | 114.6% |
| 2005 FY | 15.1 Million USD | 187.06% |
| 2004 Q2 | 5.65 Million USD | -10.8% |
| 2004 Q4 | 5.03 Million USD | 3.5% |
| 2004 Q3 | 4.86 Million USD | -13.89% |
| 2004 Q1 | 6.33 Million USD | 19.94% |
| 2004 FY | -17.35 Million USD | -173.61% |
| 2003 Q3 | 6.2 Million USD | 241.65% |
| 2003 Q4 | 5.28 Million USD | -14.85% |
| 2003 Q2 | -4.38 Million USD | -60.14% |
| 2003 Q1 | -2.73 Million USD | -199.96% |
| 2003 FY | 23.57 Million USD | 281.34% |
| 2002 Q4 | 2.73 Million USD | -4.07% |
| 2002 FY | -13 Million USD | -228.32% |
| 2002 Q1 | 2.2 Million USD | -18.12% |
| 2002 Q2 | 2.99 Million USD | 35.52% |
| 2002 Q3 | 2.85 Million USD | -4.65% |
| 2001 Q4 | 2.69 Million USD | 14.24% |
| 2001 FY | 10.13 Million USD | -21.78% |
| 2001 Q3 | 2.36 Million USD | -50.14% |
| 2001 Q2 | 4.73 Million USD | 88.46% |
| 2001 Q1 | 2.51 Million USD | -23.47% |
| 2000 Q1 | 1.51 Million USD | 86.05% |
| 2000 Q3 | 2.52 Million USD | -39.12% |
| 2000 FY | 12.95 Million USD | 83.81% |
| 2000 Q2 | 4.15 Million USD | 173.85% |
| 2000 Q4 | 3.28 Million USD | 29.9% |
| 1999 Q2 | 875 Thousand USD | 1.53% |
| 1999 Q1 | 861.78 Thousand USD | 20.34% |
| 1999 Q4 | 814.91 Thousand USD | 73.99% |
| 1999 FY | 7.04 Million USD | 99.81% |
| 1999 Q3 | 468.36 Thousand USD | -46.47% |
| 1998 Q1 | 1.12 Million USD | -5.9% |
| 1998 Q2 | 479.94 Thousand USD | -57.31% |
| 1998 Q4 | 716.14 Thousand USD | -24.55% |
| 1998 Q3 | 949.12 Thousand USD | 97.76% |
| 1998 FY | 3.52 Million USD | 0.72% |
| 1997 Q4 | 1.19 Million USD | 50.85% |
| 1997 Q3 | 791.93 Thousand USD | 0.0% |
| 1997 FY | 3.5 Million USD | -1.52% |
| 1996 FY | 3.55 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Appili Therapeutics Inc. | 8.83 Million CAD | -492.467% |
| Eupraxia Pharmaceuticals Inc. | 37.92 Million CAD | -38.056% |
| Helix BioPharma Corp. | 9.35 Million CAD | -459.538% |
| Microbix Biosystems Inc. | 10.21 Million CAD | -412.402% |
| Medicenna Therapeutics Corp. | 19.66 Million CAD | -166.267% |
| Satellos Bioscience Inc. | 6.64 Million CAD | -687.782% |
| Oncolytics Biotech Inc. | 33.79 Million CAD | -54.941% |
| Sernova Corp. | 41.13 Million CAD | -27.292% |